GLP-1 Receptor Agonists and Sustainable Obesity Care

This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.

from JAMA Internal Medicine Online First https://ift.tt/i3mQuZP